A subgroup analysis of pooled data from the pembrolizumab KEYNOTE-001, -002, and -006 trials evaluated patients with advanced melanoma and known BRAF V600E/K tumor mutations who had received pembrolizumab. The gene discussed is BRAF; the disease is melanoma.